Serina Therapeutics, Inc. Accounts Receivable
Serina Therapeutics, Inc. (SER) had Accounts Receivable of $65.00 thousand as of 2024-03-31, per its 10-Q filed 2024-05-14.
Discontinued › Balance Sheet › Assets › Assets, Current › Receivables, Net, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2024-05-14
- 2024-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $65.00K.
- 2023-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $57.00K.
- 2023-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $67.00K.
- 2023-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $6.00K.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2024-03-31 | $65.00K 10-Q · filed 2024-05-14 |
| 2023-12-31 | $57.00K 10-K · filed 2024-03-22 |
| 2023-09-30 | $67.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $6.00K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $6.00K 10-Q · filed 2023-05-12 |
| 2022-12-31 | $4.00K 10-K · filed 2024-03-22 |
| 2022-09-30 | $1.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $12.00K 10-Q · filed 2022-08-12 |
| 2021-12-31 | $25.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | $24.00K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $11.00K 10-Q · filed 2021-08-13 |
| 2021-03-31 | $48.00K 10-Q · filed 2021-05-17 |
| 2020-12-31 | $326.00K 10-K · filed 2022-03-29 |
| 2020-09-30 | $241.00K 10-Q · filed 2020-11-16 |
| 2020-06-30 | $235.00K 10-Q · filed 2020-08-14 |
| 2020-03-31 | $366.00K 10-Q · filed 2020-05-14 |
| 2019-12-31 | $363.00K 10-K · filed 2021-03-31 |
| 2019-09-30 | $234.00K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $208.00K 10-Q · filed 2019-08-14 |
| 2019-03-31 | $206.00K 10-Q · filed 2019-05-15 |
| 2018-12-31 | $131.00K 10-K/A · filed 2020-03-31 |
| 2017-12-31 | $107.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |